Early Stage Partners, LP — 2020 Investments
1 investments dated 2020 · listed companies and verified rows first · show all
SeaStar Medical develops the Selective Cytopheretic Device (SCD), a therapy that targets highly activated neutrophils and monocytes to neutralize the hyperinflammatory immune response in critically ill ICU patients facing conditions such as infection, trauma, or surgery.
BiotechHealthtechMedical DevicesDenver, US
Eric Schlorff(Executive Officer, Director)inAlvin Vitangcol(Director)Kenneth Van Heel(Director)Leslie Bottorff(Director)William White(Director)H David Humes(Director)
Co-investorsAphelion CapitalCapital Midwest FundWMU Biosciences Research & Commercialization Center
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.